Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
出版年份 2023 全文链接
标题
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
作者
关键词
-
出版物
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
Volume -, Issue -, Pages 1-27
出版商
Informa UK Limited
发表日期
2023-10-26
DOI
10.1080/10408363.2023.2266482
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
- (2023) Sofie H. Tolmeijer et al. CLINICAL CANCER RESEARCH
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
- (2023) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
- (2023) Neeraj Agarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
- (2023) Alice Bernard-Tessier et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.
- (2023) Edmond Michael Kwan et al. JOURNAL OF CLINICAL ONCOLOGY
- Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).
- (2023) Noel W. Clarke et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
- (2023) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
- (2023) Elizabeth Pan et al. MOLECULAR CANCER THERAPEUTICS
- Pan-cancer whole-genome comparison of primary and metastatic solid tumours
- (2023) Francisco Martínez-Jiménez et al. NATURE
- Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
- (2023) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
- (2023) Peter H. J. Slootbeek et al. Cancers
- Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer
- (2022) Anthony V. Serritella et al. CLINICAL CANCER RESEARCH
- Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).
- (2022) Arpit Rao et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
- (2022) Xin Gao et al. JOURNAL OF CLINICAL ONCOLOGY
- TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and potential associations with antitumor activity.
- (2022) Tanya B. Dorff et al. JOURNAL OF CLINICAL ONCOLOGY
- Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
- (2022) Matthew R Smith et al. LANCET ONCOLOGY
- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
- (2022) Karim Fizazi et al. LANCET
- Inhibitors of PARP: Number crunching and structure gazing
- (2022) Johannes Rudolph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The impact of genetic aberrations on response to radium‐223 treatment for castration‐resistant prostate cancer with bone metastases
- (2022) Alex J. Liu et al. PROSTATE
- Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment
- (2022) Soghra Bagheri et al. Pharmaceutics
- Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).
- (2022) Alice Bernard-Tessier et al. JOURNAL OF CLINICAL ONCOLOGY
- Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
- (2022) Sandra van Wilpe et al. OncoImmunology
- 1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
- (2022) F. Saad et al. ANNALS OF ONCOLOGY
- Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- (2022) Zachary Quinn et al. CLINICAL CANCER RESEARCH
- Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
- (2022) Kim N. Chi et al. CLINICAL CANCER RESEARCH
- Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
- (2022) Andrea Loehr et al. EUROPEAN UROLOGY
- BRCA Reversion Mutations in Metastatic Castration-Resistant Prostate Cancer
- (2022) Gillian Vandekerkhove EUROPEAN UROLOGY
- Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
- (2022) Joseph W. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry
- (2022) Gijs P. A. van den Bergh et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients
- (2022) Bangwei Fang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2 ‐mutated metastatic castrate‐resistant prostate cancer
- (2022) Christopher T. Su et al. PROSTATE
- Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis
- (2022) Tamás Fazekas et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate sensitive prostate cancer (SWOG S1216)
- (2021) Amir Goldkorn et al. CLINICAL CANCER RESEARCH
- Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
- (2021) Tamara L. Lotan et al. MODERN PATHOLOGY
- Clinical implications of genomic alterations in metastatic prostate cancer
- (2021) Takayuki Sumiyoshi et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms
- (2021) Hanna Tukachinsky et al. CLINICAL CANCER RESEARCH
- Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.
- (2021) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.
- (2021) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
- (2021) M. Annala et al. ANNALS OF ONCOLOGY
- Protein kinase inhibitors for the treatment of prostate cancer
- (2021) Vincent Chau et al. EXPERT OPINION ON PHARMACOTHERAPY
- Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
- (2021) Mamta Parikh et al. Scientific Reports
- Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
- (2021) Sandra van Wilpe et al. Cancers
- Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
- (2021) A. Jayaram et al. ANNALS OF ONCOLOGY
- A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer
- (2021) Daniel Westaby et al. Annual Review of Pharmacology and Toxicology
- Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer
- (2021) Harsimar B. Kaur et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
- (2021) Matti Annala et al. CLINICAL CANCER RESEARCH
- Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
- (2021) Semini Sumanasuriya et al. EUROPEAN UROLOGY
- First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).
- (2021) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
- (2021) Christopher Sweeney et al. LANCET
- Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
- (2021) Johann S de Bono et al. LANCET ONCOLOGY
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer
- (2021) Bastiaan M. Privé et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
- (2021) Suzanne Carreira et al. Cancer Discovery
- Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
- (2021) Dai Koguchi et al. Urology Case Reports
- Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
- (2021) Peter H. J. Slootbeek et al. BRITISH JOURNAL OF CANCER
- PARP Inhibition in Advanced Prostate Cancer
- (2021) Sarah E. Fenton et al. CANCER JOURNAL
- Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer
- (2021) Thanakorn Pungsrinont et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
- (2021) Corinne Maurice-Dror et al. INVESTIGATIONAL NEW DRUGS
- A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
- (2021) Elizabeth K Bancroft et al. LANCET ONCOLOGY
- ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer
- (2020) Shahrzad Rafiei et al. CANCER RESEARCH
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
- (2020) Wassim Abida et al. CLINICAL CANCER RESEARCH
- Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype
- (2020) C. Lu et al. ANNALS OF ONCOLOGY
- Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
- (2020) Andrew D. Simmons et al. BMC CANCER
- Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity
- (2020) Alexandra O. Sokolova et al. CLINICAL CANCER RESEARCH
- Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
- (2020) Cameron Herberts et al. EUROPEAN UROLOGY
- Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
- (2020) Heidi Fettke et al. EUROPEAN UROLOGY
- Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of Microsatellite Instability from Circulating Tumor DNA by Targeted Deep Sequencing
- (2020) Zhenghao Cai et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Integrating genomic features for non-invasive early lung cancer detection
- (2020) Jacob J. Chabon et al. NATURE
- Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers
- (2020) Manuel Caitano Maia et al. Nature Reviews Urology
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
- (2020) Laura S. Graham et al. PLoS One
- Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
- (2020) Manish Kohli et al. EBioMedicine
- HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
- (2020) D.J. Khalaf et al. ANNALS OF ONCOLOGY
- Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
- (2020) Pedro Barata et al. Journal for ImmunoTherapy of Cancer
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
- (2020) Padmanee Sharma et al. CANCER CELL
- Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer
- (2020) Maarten J. van der Doelen et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib
- (2020) Konrad H. Stopsack EUROPEAN UROLOGY
- Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer
- (2020) Peter H. J. Slootbeek et al. INTERNATIONAL JOURNAL OF CANCER
- BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?
- (2020) Mark C. Markowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
- (2020) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative analysis of genomic alterations across castration-sensitive and castration-resistant prostate cancer via circulating tumor DNA sequencing
- (2020) Liancheng Fan et al. JOURNAL OF UROLOGY
- PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA
- (2020) Emily N. Risdon et al. ONCOLOGIST
- First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
- (2020) Timothy A. Yap et al. Cancer Discovery
- CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer
- (2020) Tamara L. Lotan et al. CLINICAL CANCER RESEARCH
- Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer
- (2020) Laura A. Sena et al. ONCOLOGIST
- FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA ‐Mutated Metastatic Castrate‐Resistant Prostate Cancer
- (2020) Mitchell S. Anscher et al. ONCOLOGIST
- Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference
- (2020) Kendal Jensen et al. JAMA Oncology
- Neuroendocrine and Aggressive-Variant Prostate Cancer
- (2020) Nicholas Spetsieris et al. Cancers
- Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
- (2019) Gillian Vandekerkhove et al. EUROPEAN UROLOGY
- PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
- (2019) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry
- (2019) Edoardo Francini et al. PROSTATE CANCER AND PROSTATIC DISEASES
- MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
- (2019) Nicholas G. Nickols et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations
- (2019) Catherine H. Marshall et al. EUROPEAN UROLOGY
- Effectiveness of Platinum-based chemotherapy in patients with metastatic Prostate Cancer: A Systematic review and meta-analysis
- (2019) Frederico Leal et al. Clinical Genitourinary Cancer
- A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
- (2019) Elizabeth Ruth Plummer et al. JOURNAL OF CLINICAL ONCOLOGY
- Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand
- (2019) Lin Mei et al. Journal of Hematology & Oncology
- Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer
- (2019) Narges Ansari et al. Labmedicine
- Genome-wide cell-free DNA fragmentation in patients with cancer
- (2019) Stephen Cristiano et al. NATURE
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
- (2019) Alanna R. Kaplan et al. Science Translational Medicine
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
- (2019) Alec Paschalis et al. EUROPEAN UROLOGY
- Clinical implications of mismatch repair deficiency in prostate cancer
- (2019) Ramy Sedhom et al. Future Oncology
- Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
- (2019) Mev Dominguez-Valentin et al. GENETICS IN MEDICINE
- A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer
- (2019) Shona Lang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour lineage shapes BRCA-mediated phenotypes
- (2019) Philip Jonsson et al. NATURE
- DNA double-strand break repair-pathway choice in somatic mammalian cells
- (2019) Ralph Scully et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- ATM in DNA repair in cancer
- (2019) Mei Hua Jin et al. PHARMACOLOGY & THERAPEUTICS
- The BRCA2 mutation status shapes the immune phenotype of prostate cancer
- (2019) Maximilian Jenzer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis of homologous recombination
- (2019) Yueru Sun et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer
- (2019) Elie Ritch et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial
- (2019) Paul G Corn et al. LANCET ONCOLOGY
- The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
- (2019) Lisanne F. van Dessel et al. Nature Communications
- Genomics of lethal prostate cancer at diagnosis and castration resistance
- (2019) Joaquin Mateo et al. JOURNAL OF CLINICAL INVESTIGATION
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
- (2018) David A. Quigley et al. CELL
- Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
- (2018) Emmanuel S. Antonarakis et al. EUROPEAN UROLOGY
- Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
- (2018) Joaquin Mateo et al. EUROPEAN UROLOGY
- Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials
- (2018) Glenn Heller et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Prostate Cancer
- (2018) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA mismatch repair in cancer
- (2018) Marina Baretti et al. PHARMACOLOGY & THERAPEUTICS
- A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
- (2018) Michael T. Schweizer et al. PLoS One
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Matti Annala et al. Cancer Discovery
- Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
- (2018) Karim Boudadi et al. Oncotarget
- Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
- (2018) Michael M. Boyiadzis et al. Journal for ImmunoTherapy of Cancer
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage
- (2018) Catherine Handy Marshall et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
- (2018) Angela Rita Elia et al. Frontiers in Immunology
- Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
- (2018) Zafeiris Zafeiriou et al. EUROPEAN UROLOGY
- Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations
- (2018) Emmanuel S. Antonarakis et al. EUROPEAN UROLOGY
- Enhanced detection of circulating tumor DNA by fragment size analysis
- (2018) Florent Mouliere et al. Science Translational Medicine
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
- (2017) Matti Annala et al. EUROPEAN UROLOGY
- Cancer risk and survival inpath_MMRcarriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database
- (2017) Pål Møller et al. GUT
- Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
- (2017) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- The Future of Radioligand Therapy: α, β, or Both?
- (2017) Uwe Haberkorn et al. JOURNAL OF NUCLEAR MEDICINE
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
- (2017) Alexander W Wyatt et al. JNCI-Journal of the National Cancer Institute
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Precision Oncology: The Road Ahead
- (2017) Daniela Senft et al. TRENDS IN MOLECULAR MEDICINE
- Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
- (2017) Mohammad Asim et al. Nature Communications
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer
- (2017) Jianneng Li et al. eLife
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
- (2017) Alexander W Wyatt et al. JNCI-Journal of the National Cancer Institute
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- The BRCA1- 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
- (2016) Y. Wang et al. CANCER RESEARCH
- Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
- (2016) David Lorente et al. Clinical Genitourinary Cancer
- Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
- (2016) Heather H. Cheng et al. EUROPEAN UROLOGY
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- 225Ac-PSMA-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- p53 in the DNA-Damage-Repair Process
- (2016) Ashley B. Williams et al. Cold Spring Harbor Perspectives in Medicine
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2016) Alexander W. Wyatt et al. JAMA Oncology
- Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
- (2015) M. Nakazawa et al. ANNALS OF ONCOLOGY
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
- (2015) H. Beltran et al. CLINICAL CANCER RESEARCH
- Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
- (2015) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer
- (2015) Srikala S. Sridhar et al. Clinical Genitourinary Cancer
- Mechanisms and Consequences of Double-Strand DNA Break Formation in Chromatin
- (2015) Wendy J. Cannan et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer
- (2015) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma AR and abiraterone-resistant prostate cancer
- (2015) Alessandro Romanel et al. Science Translational Medicine
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- Androgen receptor signaling in prostate cancer
- (2014) Zoran Culig et al. CANCER AND METASTASIS REVIEWS
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Transcriptional Roles of PARP1 in Cancer
- (2014) Matthew J. Schiewer et al. MOLECULAR CANCER RESEARCH
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
- (2013) William L. Dahut et al. BJU INTERNATIONAL
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- GermlineBRCAMutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
- (2013) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- (2013) Gwenaelle Gravis et al. LANCET ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
- (2013) W. R. Polkinghorn et al. Cancer Discovery
- Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
- (2012) Himisha Beltran et al. EUROPEAN UROLOGY
- The role of BRCA1 in DNA double-strand repair: Past and present
- (2012) Kevin W. Caestecker et al. EXPERIMENTAL CELL RESEARCH
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- NBN Phosphorylation regulates the accumulation of MRN and ATM at sites of DNA double-strand breaks
- (2012) J Wen et al. ONCOGENE
- Dual Roles of PARP-1 Promote Cancer Growth and Progression
- (2012) M. J. Schiewer et al. Cancer Discovery
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens
- (2009) K. K. Waltering et al. CANCER RESEARCH
- Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
- (2009) Wennuan Liu et al. NATURE MEDICINE
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Homologous recombination in DNA repair and DNA damage tolerance
- (2008) Xuan Li et al. CELL RESEARCH
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1
- (2008) Marjolijn J L Ligtenberg et al. NATURE GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation